Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 484Carcinoma, Non-Small-Cell Lung 440Prostatic Neoplasms 292Lung Neoplasms 170Stomach Neoplasms 140Neoplasms 114Squamous Cell Carcinoma of Head and Neck 109Neoplasm Metastasis 97Head and Neck Neoplasms 96Esophageal Neoplasms 71Ovarian Neoplasms 57Pancreatic Neoplasms 42Urinary Bladder Neoplasms 39Sarcoma 39Nasopharyngeal Carcinoma 36Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 25Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

Pemetrexed 8Carboplatin 6Cisplatin 4Bevacizumab 4pembrolizumab 3anlotinib 3Platinum 2Paclitaxel 2tusamitamab ravtansine 1ixabepilone 1icotinib 1endostar protein 1camrelizumab 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-squamous Non-small Cell Lung Cancer × Docetaxel × Clear all
NCT03566576 2018-06-25

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Fujian Cancer Hospital

Phase NA Unknown
18 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡